A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness and safety of two different dose
schedules of DACOGEN® (decitabine) for Injection in patients with Myelodysplastic Syndromes
(MDS).